Study Confirms Positive Effect of PAE for Patients With Benign Prostatic Hyperplasia
July 21, 2016—Findings from a study that sought to confirm whether prostatic artery embolization (PAE) has a positive medium- and long-term effect in patients with symptomatic benign prostatic hyperplasia (BPH) were published by João M. Pisco, MD, et al in the Journal of Vascular and Interventional Radiology (JVIR; 2016;27:1115–1122).
As summarized in JVIR, between March 2009 and October 2014, 630 consecutive patients with BPH and moderate-to-severe lower urinary tract symptoms refractory to medical therapy for at least 6 months and those who refused any medical therapy underwent PAE. The outcome parameters were evaluated at baseline; 1, 3, and 6 months; every 6 months between 1 and 3 years; and yearly thereafter up to 6.5 years.
In the study, the mean patient age was 65.1 ± 8 years (range, 40–89 years). There were 12 (1.9%) technical failures. Bilateral PAE was performed in 572 patients (92.6%), and unilateral PAE was performed in 46 patients (7.4%).
The investigators reported that the cumulative clinical success rates at medium- and long-term follow-up were 81.9% (95% confidence interval [CI], 78.3%–84.9%) and 76.3% (95% CI, 68.6%–82.4%). There was a statistically significant (P < .0001) change from baseline to the last observed value in all clinical parameters: International Prostate Symptom Score (IPSS), quality of life (QOL), prostate volume, prostate-specific antigen, urinary maximal flow rate, postvoid residual, and International Index of Erectile Function. There were two major complications without sequelae.
PAE had a positive effect on IPSS, QOL, and all objective outcomes in symptomatic BPH; additionally, the medium- (1–3 years) and long-term (> 3–6.5 years) clinical success rates were 81.9% and 76.3%, with no urinary incontinence or sexual dysfunction reported, concluded the investigators in JVIR.